Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

326.09 +3.26 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged. 
Via Benzinga
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
The top 10 large-cap stocks in the last week were RIVN, CUK, FDX, IOT, SUZ, CVNA, FTAI, RDDT, MDB, and ALNY. Many analysts have raised their price forecasts for these stocks. 
Via Benzinga
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21, 
Via Benzinga
Topics Stocks
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday?
Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains... 
Via Benzinga
Topics Stocks
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
Via Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
Via Benzinga
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees. 
Via InvestorPlace
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare. 
Via InvestorPlace
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and... 
Via Benzinga
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
The companies are working on treatments for ATTR amyloidosis with cardiomyopathy. 
Via Investor's Business Daily
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Masters In Trading - Saturday, June 22
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
Via Talk Markets
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Alnylam Issues 2023 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
ALNY stock results show that Alnylam Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood... 
Via Benzinga
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback